MDT

101.5

+1.85%↑

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

MDT

101.5

+1.85%↑

139.72

+1.42%↑

VEEV

225.69

+2.98%↑

HQY

87.23

+3.21%↑

NEOG

10.01

+4.6%↑

Home・Aktien・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Open

BrancheGesundheitswesen

12.73 2.33

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

12.18

Max

12.73

Schlüsselkennzahlen
By Trading Economics
Einkommen	-445K -19M
Verkäufe	-3.2M 15M
Gewinnspanne	-123.636
Angestellte	120
EBITDA	-883K -16M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+48.12% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	6. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-6.1M 364M
Vorheriger Eröffnungskurs	10.4
Vorheriger Schlusskurs	12.73

Nachrichtenstimmung

By Acuity

50%

177 / 360 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

5.04 / 5.44 Unterstützung & Widerstand

ENANTA PHARMACEUTICALS INC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Jan. 2026, 23:49 UTC

Wichtige Markttreiber

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21. Jan. 2026, 21:12 UTC

Wichtige Markttreiber

Automaker Stocks Rise After Trump Calls Off European Tariffs

21. Jan. 2026, 21:00 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21. Jan. 2026, 20:29 UTC

Wichtige Markttreiber

Chip Makers Gain After Trump Calls Off European Tariffs

21. Jan. 2026, 20:04 UTC

Wichtige Markttreiber

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21. Jan. 2026, 23:48 UTC

Market Talk

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21. Jan. 2026, 23:34 UTC

Market Talk

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21. Jan. 2026, 22:39 UTC

Ergebnisse

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21. Jan. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21. Jan. 2026, 21:35 UTC

Akquisitionen, Fusionen, Übernahmen

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21. Jan. 2026, 21:19 UTC

Ergebnisse

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21. Jan. 2026, 20:45 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Borse Group to Acquire Allfunds for $6.19B

21. Jan. 2026, 20:36 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21. Jan. 2026, 20:31 UTC

Market Talk

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21. Jan. 2026, 20:27 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21. Jan. 2026, 20:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21. Jan. 2026, 20:27 UTC

Market Talk

Was It a 'TACO' Event? -- Market Talk

21. Jan. 2026, 20:26 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21. Jan. 2026, 20:23 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21. Jan. 2026, 20:21 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21. Jan. 2026, 20:19 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse Group Agrees to Buy Allfunds

21. Jan. 2026, 20:08 UTC

Ergebnisse

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21. Jan. 2026, 20:03 UTC

Market Talk

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21. Jan. 2026, 19:51 UTC

Market Talk

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21. Jan. 2026, 19:43 UTC

Market Talk

U.S. Ethanol Production Expected to Slip -- Market Talk

21. Jan. 2026, 19:31 UTC

Market Talk

Gold Settles at Fresh All-Time High -- Market Talk

21. Jan. 2026, 19:24 UTC

Ergebnisse

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21. Jan. 2026, 19:10 UTC

Market Talk

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21. Jan. 2026, 18:57 UTC

Market Talk

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Peer-Vergleich

Kursveränderung

ENANTA PHARMACEUTICALS INC Prognose

Kursziel

By TipRanks

48.12% Vorteil

12-Monats-Prognose

Durchschnitt 18.5 USD 48.12%

Hoch 20 USD

Tief 17 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für ENANTA PHARMACEUTICALS INC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für ENANTA PHARMACEUTICALS INC – Dist abgegeben haben.

Technischer Score

By Trading Central

5.04 / 5.44Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There are no events.

Stimmung

By Acuity

177 / 360 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.